Welcome to the e-CCO Library!

DOP028: Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Kemp1*, L. Dibley2, U. Chauhan3, K. Greveson4, S. Jaghult5, K. Ashton6, S. Buckton7, J. Duncan8, P. Hartmann9, N. Ipenburg10, L. Moortgat11, R. Theeuwen12, M. Verway13, L. Younge14, P. Bager15

Created: Thursday, 21 February 2019, 9:14 AM
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van Stappen T.*1, Vande Casteele N.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Van Stappen T.
Crohn's disease, Ulcerative colitis, Anti-TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Infliximab
Files: 1
DOP029: Outcomes of a managed switching program changing IBD patients established on originator infliximab to biosimilar infliximab
Year: 2016
Source: ECCO'16 DOP
Authors: Cummings F.
anti-TNF, biosimilars, infliximab, real world data
Files: 1
DOP029: Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Bettey1, L. Downey1, C. Underhill1, J. Callaghan1, M. Rush2, I. Ahmed1, F. Cummings*1

Created: Friday, 22 February 2019, 9:49 AM
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Kollen1, A. Leroyer2, A. Breton3, M. Fumery4, G. Savoye5, J. Lemale6, D. Morin1, B. Pariente7, E. Mas3, D. Turck8, M. Al Khouri1, P. Blanc9, C. Gower2, G. Pineton de Chambrun9*

Created: Thursday, 21 February 2019, 9:14 AM
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Pineton de Chambrun Guillaume
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP02: Developing explicit thresholds for outcomes to inform (GRADE) Evidence to Decision frameworks for Inflammatory Bowel Disease guidelines.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Shaban, Nader
Created: Tuesday, 30 April 2024, 5:03 PM
DOP02: Increasing incidence of Inflammatory Bowel Disease in a high prevalence country: A nationwide study in Finland
Year: 2022
Source: ECCO'22
Authors: Kontola, K.(1);Oksanen, P.(2,3);Huhtala, H.(4);Jussila, A.T.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP02: Single cell RNA sequencing of Ulcerative Colitis and Crohn's Disease tissue samples informs the selection of Triggering Receptors Expressed on Myeloid Cells 1 (TREM1) as a target for the treatment of Inflammatory Bowel Diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Grant, S.(1)*;Johnson, K.(1);Thomas, T.(2);Honig, G.(1);Bielecki, P.(1);Dendrou, C.(3);Guo, S.(1);Kulicke, R.(1);Li, P.(1);L'Italien, L.(1);Spies, N.(1);Stransky, N.(1);Uhlig, H.(4);Varma, M.(1);Travis, S.(5);Buckley, C.(2);Magram, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP02: Supplementation with butyrate producing bacteria reduces tumor load in a mouse model of colitis associated cancer
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Ana Montalban-Arques
Created: Tuesday, 28 May 2019, 3:32 PM
Environmental factors, Microbiota, IBD-associated cancer, Colorectal cancer, IBD and malignancy, Microbiota
Files: 1
DOP02: Supplementation with butyrate producing bacteria reduces tumour load in a mouse model of colitis-associated cancer
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Montalban Arques*1, I. Olivares Rivas1, K. Atrott1, C. Gottier1, S. Lang1, G. Leventhal2, T. DeWouters3, M. Scharl1, M. Spalinger1

Created: Friday, 22 February 2019, 9:41 AM
DOP02: The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
Year: 2020
Source: ECCO'20 Vienna
Authors: Vaios Svolos
Created: Tuesday, 23 June 2020, 5:40 PM
DOP02: The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
Year: 2020
Source: ECCO'20 Vienna
Authors: Vaios Svolos
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP02: αEβ7 positive γδ T cells are associated with mucosal healing in Ulcerative Colitis and have a homeostatic immunophenotype
Year: 2021
Source: ECCO'21 Virtual
Authors: Dart, R.(1,2);Zlatareva, I.(1,2);Irving, P.(1,3);Hayday, A.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP03 The impact of elemental diet on the human gut microbial structure and intestinal metabolites
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Miyoshi1, D. Saito1, M. Nakamura2, M. Miura1, T. Mitsui1, T. Kudo3, S. Murakami3, M. Matsuura1, T. Hisamatsu1

Created: Thursday, 30 January 2020, 10:12 AM
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's disease: a dual centre “real world” study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Srinivasan A.*1, Vasudevan A.1,2,3, McFarlane A.1, Gibson P.2,3, Sparrow M.2,3, van Langenberg D.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn’s Disease: A dual centre ‘real world’ study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Srinivasan A.
Crohn's disease, Health economic analysis, Anti-TNF agents, Treat to target
Files: 1
DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Smits*, L. Derikx, J. Drenth, D. de Jong, A. van Esch, F. Hoentjen

Created: Friday, 22 February 2019, 9:49 AM